Development safety update reports and proposals for effective and efficient risk communication

Drug Safety

Volumn 33, Issue 5, 2010, Pages 341-352

  Urushihara, Hisashi ^a   Kawakami, Koji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEVELOPMENT SAFETY UPDATE REPORT; DRUG INFORMATION; DRUG SAFETY; ETHICS; FOOD AND DRUG ADMINISTRATION; LIFE CYCLE; MASS COMMUNICATION; MEDICAL DOCUMENTATION; NOTE; PERIODIC SAFETY UPDATE REPORT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL;

ADVERSE DRUG REACTION REPORTING SYSTEMS; COMMUNICATION; DRUG APPROVAL; DRUG TOXICITY; DRUGS, INVESTIGATIONAL; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; RISK ASSESSMENT;

EID: 77951140967     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11533780-000000000-00000     Document Type: Note

References (11)

1. The Council for International Organizations of Medical Sciences. The development safety update report (DSUR): harmonizing the format and content for periodic safety reporting during clinical trials. Report of CIOMS Working Group VII. Geneva: CIOMS, 2006
2. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Draft consensus guideline. Development safety update report E2F. Current step 2 version, 2008 Jun 5 [online]. Available from URL: http://www.ich.org/LOB/media/MEDIA4727.pdf [Accessed 2009 Jan 26]
3. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Clinical safety data management: periodic safety update reports for marketed drugs E2C (R1). Current step 4 ver-sion 2005 Nov [online]. Available from URL: http://www.ich.org/LOB/media/MEDIA477.pdf [Accessed 2009 Jan 26]
4. The Council for International Organizations of Medical Sciences. Management of safety information from clinical trials. Report of CIOMS Working Group VI. Geneva: CIOMS, 2005
5. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Clinical safety data management: definitions and standards for ex-pedited reporting. Current step 4 version, 1994 Oct 27 [online]. Available from URL: http://www.ich.org/LOB/media/MEDIA436.pdf [Accessed 2009 Jan 26]
6. The Council for International Organizations of Medical Sciences. Guidelines for preparing core clinical safety information on drugs. Report of CIOMS Working Group III (second edition). Geneva: CIOMS, 1999
7. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [online]. Available from URL: http://www. ich.org/cache/compo/276-254-1.html [Accessed 2010 Mar 30]
8. Temple R. Meta-analysis and epidemiologic studies in drug development and postmarketing surveillance. JAMA 1999; 281 (9): 841-844 (Pubitemid 29113746)
9. Hartford CG, Petchel KS, Mickail H, et al. Pharmaco-vigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines. Drug Saf 2006; 29 (8): 657-673 (Pubitemid 44175037)
10. Institute of Medicine of The National Academies. The fu-ture of drug safety: promoting and protecting the health of the public. Washington, DC: The National Academies Press, 2007
11. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline. Pharmacovigilance planning E2E. Current step 4 version, 2004 Nov 18 [online]. Available from URL: http://www. ich.org/LOB/media/MEDIA1195.pdf [Accessed 2009 Jan 26]